bluuebunny/crossref_metadata_2025_split huggingface dataset:
1200-P: The Prevalence of Obesity-Associated Loss of Lean Muscle Mass
Authors: MURDOCK DANA J. , WU NING , GLASS DAVID J. , GRIMSBY JOSEPH S. , CALLE ROBERTO A. , DONAHUE STEPHEN , SLEEMAN MARK , SANCHEZ ROBERT J. 
Published: May 2022

Sarcopenia, originally defined as age-related low muscle mass and function, has also been used to describe the loss of muscle mass and quality among certain populations, such as sarcopenic obesity (SO) . SO refers to loss of muscle and function in obese subjects; however, given age is not a factor in SO, we classified SO as obesity with low lean muscle mass (OLLMM) . Given the paucity of data in OLLMM, the purpose was to describe the prevalence of OLLMM in the US. Data from NHANES 2017-2018 were used to estimate the prevalence of OLLMM in adults ≥20 yrs of age. OLLMM was defined as DEXA-assessed low appendicular lean mass, adjusted for BMI (men &lt;0.789, women &lt;0.512) and obesity (body fat%: men &gt;25%, women &gt;35%) . Since DEXA was only measured in those aged 20-59 in NHANES 2017-2018, we utilized logistic regression models to predict OLLMM from NHANES 1999-20for those ≥60 yrs. The prevalence of OLLMM was estimated overall, by sex, age group, and diabetes status (prediabetes and T2DM) . We extrapolated results to the US using NHANES sampling weights. Of the 4174 adults (representing 181M US adults) , we identified 827 (28.8M, 15.9% of the US pop.) with OLLMM. Older adults had higher prevalence of OLLMM as did those with prediabetes and T2DM (Figure 1) . The prevalence of OLLMM in the US is high. While the prevalence of OLLMM was higher with age, its prevalence was also high in diabetics, regardless of age. Clinicians should monitor for OLLMM among obese T2DM patients.

Disclosure
D.J. Murdock: Employee; Regeneron Pharmaceuticals Inc. Stock/Shareholder; Regeneron Pharmaceuticals Inc. N. Wu: Employee; Regeneron Pharmaceuticals Inc. Stock/Shareholder; Regeneron Pharmaceuticals Inc. D.J. Glass: Employee; Regeneron Pharmaceuticals Inc. Stock/Shareholder; Regeneron Pharmaceuticals Inc. J.S. Grimsby: Employee; Regeneron Pharmaceuticals Inc. Stock/Shareholder; Regeneron Pharmaceuticals Inc. R.A. Calle: Employee; Regeneron Pharmaceuticals Inc. Stock/Shareholder; Regeneron Pharmaceuticals Inc. S. Donahue: Employee; Regeneron Pharmaceuticals Inc. Stock/Shareholder; Regeneron Pharmaceuticals Inc. M. Sleeman: Employee; Regeneron Pharmaceuticals Inc. Stock/Shareholder; Regeneron Pharmaceuticals Inc. R.J. Sanchez: Employee; Regeneron Pharmaceuticals Inc. Stock/Shareholder; Regeneron Pharmaceuticals Inc.

Funding
Supported by Regeneron Pharmaceuticals, Inc.
1209-P: Genetic Subtypes of Prediabetes, Healthy Lifestyle, and Risk of Type 2 Diabetes in U.S. Hispanics
Authors: LI YANG , CHEN GUOCHONG , MOON JEE-YOUNG , SOTRES-ALVAREZ DANIELA , DAVIGLUS MARTHA L. , PIRZADA AMBER , MATTEI JOSIEMER , PERREIRA KRISTA M. , WASSERTHEI-SMOLLER SYLVIA , WANG TAO , KAUFMAN JOEL D. , KAPLAN ROBERT , QI QIBIN 
Published: May 2022

Prediabetes is a heterogenous metabolic condition. We calculated 5 pathway-based partitioned polygenetic risk scores (pPRS: beta-cell, proinsulin, obesity, lipodystrophy and liver/lipid scores) based on 94 type 2 diabetes (T2D) -associated variants in 3677 individuals with prediabetes from the Hispanic Community Health Study/Study of Latinos. Based on these 5 pPRS, we identified 6 subtypes of prediabetes (n=488∼742 in each cluster) with different pPRS patterns by consensus clustering (Fig 1A) . Phenotypic patterns were consistent with pPRS patterns in these subtypes (Fig 1B; e.g., Cluster 1 had much lower beta-cell score, higher obesity and liver/lipid scores, and higher HOMA-B, BMI and HOMA-IR compared to other clusters) . These subtypes had similar levels of fasting glucose, HbA1c and 2h glucose at baseline but different risk of incident T2D over 6 years (Fig 1C) . Individuals in Cluster 6 featured with a very low proinsulin score had the highest risk of T2D (RR=1.42 [95% CI 1.13, 1.80] compared to Cluster 1) . We examined the association between a lifestyle score, using BMI, alcohol intake, smoking, physical activity and diet, and risk of T2D across 6 subtypes and found significant associations only in Cluster 1 (RR=0.76 [0.62, 0.93]) and Cluster 5 (RR=0.79 [0.67, 0.92]) . In US Hispanics, we identified 6 genetic subtypes of prediabetes which may differ in the development of T2D and benefits from healthy lifestyle.

Disclosure
Y.Li: None. T.Wang: None. J.D.Kaufman: None. R.Kaplan: None. Q.Qi: None. G.Chen: None. J.Moon: None. D.Sotres-alvarez: None. M.L.Daviglus: None. A.Pirzada: n/a. J.Mattei: None. K.M.Perreira: None. S.Wasserthei-smoller: None.
121-LB: Prescribing Patterns of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure With or Without Type 2 Diabetes
Authors: BERMUDEZ SARAH R. , ANDERSON JOE R. , RAY GRETCHEN 
Published: May 2022

The goal of heart failure (HF) pharmacotherapy is to improve disease-related morbidity and mortality. Recent clinical trials demonstrated a reduction in cardiovascular death and HF-related hospitalizations with the addition of sodium glucose co-transporter 2 inhibitors (SGLT2i) in patients with HF with reduced ejection fraction (HFrEF) , as well as HF with preserved ejection fraction (HFpEF) with or without type 2 diabetes (T2D) . The objective of this study was to identify SGLT2i prescribing rates in these patients and to identify predictors of drug class utilization. The University of New Mexico (UNM) Health Sciences Center IRB approved this retrospective, single-center, descriptive study. Individuals ≥ 18 years with a diagnosis of HF, an eGFR of ≥ 20 ml/min/1.73m2, and a visit to the UNM Hospital system between August 17, 2020 to August 16, 2021 were included. Patients were excluded if they were diagnosed with type 1 diabetes or had no documented EF in their patient chart. A total of 2,905 patients with HF were identified, of which 1,101 were randomly reviewed. After exclusion, the study sample included: 377 with HFrEF, 335 with HFpEF, and 88 with HF with mid-range ejection fraction. The mean age was 65 years; 60% were female; 76% were white; 47% were Hispanic; and 49% had established atherosclerotic cardiovascular disease. Overall, 42% (n = 339) had T2D with a mean A1C of 8.0%. SGLT2is were prescribed in 6.5% of patients overall, 14.7% of patients with T2D, and 0.4% of patients without T2D. Predictors of SGLT2i prescribing were: T2D (OR = 38.4; 95% CI, 8.9 - 165.58) , HFrEF (OR = 3.7; 95% CI, 1.79 - 7.47) , having a cardiology provider (OR = 2.2; 95% CI, 1.79 - 7.47) , being seen by a pharmacist with prescriptive authority (OR = 4.1; 95% CI, 2.01 - 8.26) , and enrollment in UNM’s patient assistance program (OR = 2.3; 95% CI, 1.08 - 4.97) . Despite guideline recommendations, SGLT2is are underutilized in patients with HF with or without T2D. Future studies are needed to determine the barriers to utilization.

Disclosure
S. R. Bermudez: None. J. R. Anderson: None. G. Ray: None.
1212-P: Cost-Related Medication Nonadherence in Alabama's Medicaid Population with Diabetes
Authors: NESS EMILY C. , JUAREZ LUCIA , HOWELL CARRIE R. , HOHMANN LINDSEY , CHERRINGTON ANDREA , PRESLEY CAROLINE A. 
Published: May 2022

Background: Cost-related medication nonadherence (CRMN) occurs when an individual takes less medication than what is prescribed due to difficulty affording their medications. In adults with diabetes, medication nonadherence is associated with worse glycemic control and increased healthcare costs. The goal of this study was to determine what proportion of Alabama’s Medicaid population with diabetes experiences CRMN and to evaluate for potential risk factors for CRMN in this financially-at-risk population.
Methods: We conducted a cross-sectional study surveying a population-based sample of adults (ages 19-64) with diabetes covered by Alabama Medicaid. We classified participants as experiencing CRMN if they responded yes to “Not including over the counter medications, was there a time in the past 12 months when you didn't take your medication as prescribed because of cost?” Using multivariable logistic regression, we examined what variables were associated with CRMN adjusting for demographic and clinical factors (insulin use, diabetes duration, receipt of care coordination, and self-rated health) .
Results: We included 1893 of 2235 (84.7%) participants who completed the survey and had complete data for the variables of interest in the analysis. This sample was predominantly nonwhite (60.7%) , female (73.9%) with a mean age of 52 ±10.1 years. Overall, 23.7% of participants reported CRMN. In the fully adjusted model, insulin use (OR 1.41, 95% CI 1.11, 1.79) , use of a discount prescription plan (OR 1.55, 95% CI 1.20, 2.00) , and self-report of poor health (OR 1.67, 95% CI 1.33, 2.09) were significantly associated with CRMN.
Conclusion: We found that almost a quarter of a population-based sample of adults with diabetes covered by Alabama Medicaid experienced cost-related medication nonadherence. More research is needed to determine how to address this among this vulnerable population.

Disclosure
E.C.Ness: None. L.Juarez: None. C.R.Howell: None. L.Hohmann: None. A.Cherrington: Consultant; Bayer AG, Other Relationship; Novo Nordisk. C.A.Presley: None.

Funding
National Institute of Diabetes and Digestive and Kidney Diseases (R18DK109501) UAB Diabetes Research Center (P30 DK079626)
122-OR: Association between Annual Wellness Visits and Major Amputations among Medicare Beneficiaries in the Diabetes Belt
Authors: LOBO JENNIFER M. , KIM SOYOUN , KANG HYOJUNG , SOHN MIN-WOONG 
Published: May 2022

Objective: Annual Wellness Visits (AWVs) are yearly visits for Medicare beneficiaries that include discussing preventive care needs and scheduling future preventive care services. Our prior work found that AWVs are associated with increased utilization of preventive care for diabetes patients, including uptake of foot exams. Our objective is to determine whether AWVs are associated with a reduced risk of major lower-extremity amputations (MLEAs) for patients in the Diabetes Belt.
Methods: Our analysis used a sample of approximately 900,000 Medicare Fee-for-Service beneficiaries from 2015 that lived in the Diabetes Belt and surrounding areas. The Diabetes Belt is a region of 644 counties in the Appalachian and deep south areas of the US identified by the CDC in 20 that continues to have a high prevalence. We used multivariable logistic regression to examine the association between AWVs and MLEAs in 2015, adjusting for demographic factors, comorbidities, major risk factors including diabetic foot ulcers, neuropathy, peripheral vascular disease, and access to care factors.
Results: The rate of MLEAs was significantly lower among patients in the Diabetes Belt who had an AWV in the last year. The odds of MLEAs were 36% lower in patients who used AWVs in the same year compared to those who did not, adjusting for all covariates. We also found that patients in the Diabetes Belt had about 27% higher odds of having an MLEA compared to those residing in the surrounding areas.
Discussion: Patients who used AWVs may have had their diabetic foot examined sooner to prevent a major adverse outcome than those who did not. Policy makers should prioritize incentives for having patients participate in AWVs to help reduce MLEAs.

Disclosure
J.M.Lobo: n/a. S.Kim: None. H.Kang: None. M.Sohn: None.

Funding
NIH/NIDDK R01DK113295
1230-P: Patient-Reported Outcomes (PROs) to Treatment in Type 2 Diabetes (T2D) from the International Diabetes Management Practices Study (IDMPS)
Authors: ASCHNER PABLO , GAGLIARDINO JUAN J. , ILKOVA HASAN M. , RAMACHANDRAN AMBADY , MBANYA JEAN CLAUDE , SHESTAKOVA MARINA V. , PILORGET VALERIE , MELAS-MELT LYDIE , CHANTELOT JEAN-MARC , CHAN JULIANA C. 
Published: May 2022

Introduction: Treatment acceptance and self-management are essential for achieving better HbA1c in people with diabetes.
Methods: IDMPS is an international, observational study investigating care practices and clinical profiles of people with diabetes in developing countries. This analysis of Wave 8 evaluated PROs in people with T2D and their associations with glycemic control using 1) the chronic treatment acceptance questionnaire (ACCEPT) to assess acceptance of long-term medication advantages/disadvantages, and 2) the diabetes self-management questionnaire (DSMQ) to assess health-related behaviors.
Results: Of 2475 people with T2D (mean ± SD age 58 ± 12 years, 51% women, diabetes duration ± 8 years, BMI 31 ± 6 kg/m2, HbA1c 8.0 ± 1.8 %, 43% on insulin, HbA1c &lt;7 % 31%) from 13 countries, most completed ACCEPT (99%) and DSMQ (99%) . Acceptance was high for medication effectiveness and side effects, but low for number of medications and their duration (Figure A) . Scores for self-management were low, especially physical activity (Figure B) . Multivariate analyses did not show association of HbA1c &lt;7 % with higher ACCEPT scores (bar effectiveness score) , regardless of treatment.
Conclusions: Despite high medication acceptance in developing countries, low self-management calls for further education to improve medication effectiveness.

Disclosure
P.Aschner: Advisory Panel; Merck & Co., Inc., Sanofi, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. J.C.Chan: Board Member; Asia Diabetes Foundation, Consultant; Bayer AG, Boehringer Ingelheim International GmbH, Celltrion, Merck Sharp & Dohme Corp., Roche Diabetes Care, Viatris Inc., Research Support; Applied Therapeutics, AstraZeneca, Eli Lilly and Company, Hua Medicine, Servier Laboratories, Stock/Shareholder; GemVCare Ltd. J.J.Gagliardino: None. H.M.Ilkova: Advisory Panel; Novo Nordisk. A.Ramachandran: None. J.Mbanya: Advisory Panel; Novo Nordisk, Sanofi, Servier Laboratories. M.V.Shestakova: None. V.Pilorget: None. L.Melas-melt: None. J.Chantelot: Employee; Sanofi, Stock/Shareholder; Sanofi.

Funding
Sanofi
1232-P: Beta-Cell Function and Type 2 Diabetes in Africans and Asian Indians
Authors: STAIMEZ LISA R. , SHAH ROHAN , DEEPA MOHAN , MATSHA TANDI E. , ANJANA RANJIT MOHAN , ERASMUS RAJIV T. , MOHAN VISWANATHAN , MABUNDO LILIAN , DUBOSE CHRISTOPHER , NARAYAN K.M. VENKAT , DAGOGO-JACK SAMUEL , KENGNE ANDRE PASCAL , SUMNER ANNE E. 
Published: May 2022

The role of β cell dysfunction in the development of type 2 diabetes (DM) is not understood across populations with different levels of insulin resistance. We examined β-cell function in two cohorts of Africans and compared them to Asian Indians. Adults without known DM were examined in 3 cohorts: (1) Mixed Ancestry Africans (MAA, n=1112) living in South Africa, (2) African-born Black immigrants living in United States (A-US, n=529) and born in West, Central or East Africa and (3) Asian Indians (n=1751) living in Chennai, India. OGTT were performed with fasting and 2h glucose and insulin levels obtained. Insulin resistance was defined as HOMA-IR above cohort-specific upper quartile. Beta-cell failure was defined as hyperglycemia without insulin resistance. Beta-cell secretion (HOMA-β) and insulin resistance between ethnicities by ANOVA were compared. MAA were older than A-US or Asians [ (MAA: mean 46y SD 14) , A-US) (39y, SD 10) , Asians (39y, SD 11) with more % female (MA: 73%, A-US 36%, Asians 64%) . Newly diagnosed DM was similar across cohorts (MAA: 6.4%, A-US 7.0%, and Asians 8.1%) . When pooled, 54% total had β-cell failure as the predominant etiology of DM. Fasting glucose, adjusted for age, sex, and BMI, was highest in AI (MAA: 90 mg/dL, SE 0.8; A-US 92, SE 1.1; Asians 101, SE 0.6) . However, A-US had highest 2h glucose (MAA: 97 mg/dL, SE 2.5; A-US 128, SE 4.0; Asians 107, SE 1.8) . In the normal weight BMI group (BMI:18.5-25.0 kg/m2) adjusted for age and sex, HOMA-β was lowest in Asians [97.7, SE 14.6] and 3 times higher in MAA vs. A-US (MAA 151.6, SE 88.3; A-US 48.5, SE 143.6) , despite similar HOMA-IR [MAA: 1.1, SE 0.1; A-US: 1.1 SE 0.1]. The difference in HOMA-β between overweight and obesity strata was modest in Asians and A-US vs. MAA (MAA: 90.9, A-US: 21.6, Asians: 0.9) . Overall, β-cell function was heterogeneous across African cohorts and lowest in Asians. Differences in average β-cell function between overweight and obese participants suggest insulin secretion may be less available to A-US and Asians compared to the MAA.

Disclosure
L.R.Staimez: None. K.Narayan: n/a. S.Dagogo-jack: Consultant; AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Sanofi. A.Kengne: None. A.E.Sumner: None. R.Shah: None. M.Deepa: None. T.E.Matsha: None. R.Anjana: None. R.T.Erasmus: Speaker's Bureau; Abbott. V.Mohan: None. L.Mabundo: None. C.Dubose: None.
1233-P: Racial/Ethnic Differences in the Prevalence of Diagnosed Anemia in Adults with Type 2 Diabetes
Authors: BOARD CHRISTINE , GOPALAN ANJALI , KARTER ANDREW J. , GRANT RICHARD W. , SOFRYGIN OLEG 
Published: May 2022

Individuals with anemias are often excluded from diabetes research when the population or outcome of interest is defined by HbA1c, as abnormal red blood cell turnover rates raise concern about the accuracy of measured HbA1c values. While racial/ethnic differences in the prevalence of certain anemias are well-known, the potential bias introduced by excluding individuals with anemias from research samples is less studied. We examined the prevalence of diagnosed anemias by race/ethnicity in a population of adults diagnosed with diabetes. Using data from a large healthcare system, we identified adults (≥21 years) diagnosed with type 2 diabetes from 2010-2016. We used ICD-9/codes to identify individuals diagnosed with anemia in the year prior to diabetes diagnosis and inherited hemoglobinopathies through follow-up. We used chi-square tests to compare the prevalence of these diagnoses by race/ethnicity. Among 78,2individuals, 5,434 (6.9%) had an anemia diagnosis in the 12 months prior to their diabetes diagnosis, with the most common being unspecified anemia (3.3%) and iron deficiency anemia (2.3%) . Black adults had the highest prevalence of any anemia (11% vs. Other race/ethnicity 8.8% vs. White 7% vs. Latino 6.1% vs. Asian 5.9%, p≤.0001) , unspecified anemia (5.4% vs. Other race/ethnicity 3.8% vs. White 3.5% vs. Latino 2.8% vs. Asian 2.4%, p≤.0001) , and iron deficiency anemia (3.6% vs. Other race/ethnicity 2.9% vs. White 2.2% vs. Latino 2.4% vs. Asian 1.9%, p≤.0001) . Black and Asian adults had the highest prevalence of inherited hemoglobinopathies (Asian 2.3% vs. Black 1.9% vs. Other race/ethnicity 1.3% vs. White 0.3% vs. Latino 0.3%, p≤.0001) .
In conclusion, among adults diagnosed with diabetes, Black adults had the highest prevalence of diagnosed anemias (&gt;1 in Black adults had a diagnosis) . Excluding individuals from diabetes research based on diagnosis of anemia may disproportionately impact the relevance of the findings to Black adults.

Disclosure
C.Board: None. A.Gopalan: None. A.J.Karter: Research Support; Dexcom, Inc. R.W.Grant: None. O.Sofrygin: None.

Funding
National Institutes of Health (1R21DK130018-01)
1242-P: Prevalence of Newly Detected Diabetes and Glycemic Status of People with Diabetes Already on Treatment: Results from a Nationwide Community Screening Program by RSSDI.
Authors: PARIKH RAKESH M. , GUPTA AMIT , SABOO BANSHI D. , CH VASANTH K. , AGARWAL SANJAY , MAKKAR BRIJ M. , BHATTACHARYYA SUPRATIK , CHITTAWAR SACHIN , NANDITHA ARUN , KOVIL RAJIV R. , CHAWLA SR., PURVI M. 
Published: May 2022

Background: Several studies have suggested that prevalence of diabetes in India is increasing, a large number of people remain undiagnosed, and overall glycemic control is poor among patients with diabetes. Although there is paucity of data from large population studies. Current study was aimed at analyzing the data collected during the One Nation, One Day, One Million Tests campaign by the Research Society for the Study of Diabetes in India (RSSDI)
Methodology: Data collected from the One Nation, One Day, One Million Tests campaign by the Research Society for the Study of Diabetes in India (RSSDI) was retrospectively analyzed. A total data of 225955 adults was included in the analysis out of which 142391 (63%) were males while 83564 (37%) were females.
Results: 78694 (34.8%) subjects reported to have preexisting diabetes while 21380 (9.5%) were detected to have diabetes for the first-time during the screening program. Total prevalence of diabetes in the cohort was 100074 (44.3%) .
Among people with preexisting diabetes, 68669 (87.3%) reported to be on treatment for diabetes. 17646 of them presented in fasting state and 14834 (21.6%) of them had fasting sugar above 130 mg/dl. Random blood sugar was tested for 423diabetic subjects on treatment, out of which 28335 (41.3%) had random blood sugar more than 180 mg/dl. Overall, 62.9% (43169) of diabetes patients on treatment had their blood sugar values beyond target range.
Conclusions: High prevalence of newly detected diabetes in the cohort re-emphasizes the need for aggressive screening for early detection of diabetes in the Indian population. Although the number of people who reported to be on treatment for diabetes was better in this cohort compared to earlier studies, only one third of these subjects had their sugar levels under control.

Disclosure
R.M.Parikh: None. R.R.Kovil: None. P.M.Chawla: Speaker's Bureau; Biocon, Boehringer Ingelheim International GmbH, Eris Lifesciences Ltd., Novo Nordisk, Sanofi. A.Gupta: Speaker's Bureau; Lupin Pharmaceuticals, Inc., Medtronic, Novartis AG, Novo Nordisk, Sanofi. B.D.Saboo: None. V.K.Ch: None. S.Agarwal: Speaker's Bureau; Novo Nordisk, Roche Diabetes Care, Sanofi, USV Private Limited. B.M.Makkar: None. S.Bhattacharyya: None. S.Chittawar: None. A.Nanditha: None.
1261-P: Is Glycemic Control Better in Adults with Type 1 Diabetes When Office Visits are Supplemented with Telehealth Visits?
Authors: TOSCHI ELENA , ADAM ATIF , SLYNE CHRISTINE , LAFFEL LORI M. , MUNSHI MEDHA 
Published: May 2022

Objective: Since the COVID-pandemic began, instead of in-office care alone, many institutions implemented hybrid care (in-office + telemedicine) . It is not known if hybrid care is as effective as in-office visits in regards to achieving glycemic goals.
Methods: Clinical characteristics of adults with type 1 diabetes (T1D) (age ≥40 years) were retrieved from electronic health records from two periods: in-office model before the pandemic (April 2019-March 2020) and hybrid-care model during the pandemic (September 20pril 2021) . Patients were stratified by age.
Results: Overall, 1,820 patients were evaluated, 66% younger (40-64 years: mean age 52±7yrs, 52% female, 53% CGM users, 56% pump users) and 34% older (≥65 years: mean age 72±5yrs, 55% female, 53% CGM users, 38% pump users) . A1c using hybrid-care improved in both younger (7.8±1.2 vs. 7.6±1.2%; p=0.005) and older adults (7.6±0.9 vs. 7.4±1%; p=0.02) , compared to in-office care. Within the hybrid-care model period, poor glycemic control was associated with a higher number of hybrid visits, and more in-office missed appointments, while pump use was associated with lower A1c.
Conclusion: Compared with in-office care, hybrid care was effective at maintaining glycemic control in both younger and older adults with T1D. Prospective studies are needed to understand the use of hybrid-care for the management of adults with T1D.

Disclosure
E.Toschi: Consultant; Medtronic. A.Adam: None. C.Slyne: None. L.M.Laffel: Advisory Panel; Medtronic, Roche Diabetes Care, Consultant; Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompé, Insulet Corporation, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk, Provention Bio, Inc. M.Munshi: Consultant; Sanofi.